Daunorubicine is an antibiotic and chemotherapeutic of the antracycline family. This is a part of prescription medication for treating acute myeloid and lymphatic leukemia. It is also being accredited to treat the rare Karposi's sarcoma.
This medication slows the growth of cancer cells in the body and eventually kills them off. The treatment is performed together with other chemotherapy drugs like cytarabine and its administration depends on the type of tumor and the degree of response. Daunorubicine is also used to treat neuroblastoma.
Daunorubicine is out there as daunorubicin hydrochloride and daunorubicin citrate liposome. Daunorubicin comes as a liquid form or as a powder to be mixed with liquid and injected into a vein by a doctor as the formula is able to penetrate body tissue and reach cancer cells easily because of its smaller size. When daunorubicin is used to treat AML, it is usually injected once a day on certain days of your treatment period. When daunorubicin is designed to care for AML, it's usually injected once a day on certain days of your treatment period. When daunorubicin is utilized to care for ALL, it is commonly injected once in a week. The time of treatment will depend on the types of drugs you are taking, how well your body type responds to them, and the kind of cancer you have.
Before receiving Daunorubinine injection, tell the doctor about your past or existing medical history or condition. About making Daunorubicine, a vial is filled with 4 mL of sterile water for injection and slowly turned until the material is fully dissolved in water. Each vial offers 20 mg of Daunorubicine, then the specified dosage is drawn accompanied by a syringe already containing 10 to 15 mL of 0.9% sodium chloride solution. The solution is then injected in a rapidly flowing 5% dextrose injection or 0.9 sodium chloride solution. It is not recommended to give Daunorubicine with other medications, particularly heparin.
The dosage of Daunorubicine varies from person to person, depending on the patient’s age, area of the body surface and condition. Patients under 60years of age with acute nonlymphocytic leukemia is suggested a dosage of 45mg/m2 per day of Daunorubicine IV infusion and given on the first 3days of the first course of treatment. The other medication, cytosine arabinoside, they need to be given 100 mg/m2/ per day IV infusion dosage every day for a few days in direction of the first course of treatment and 5 days in the direction of succeeding courses of treatment.
The dosage for children is decided based on the affected role's condition, age, body surface area and medical history. Usually , a dose of 25mg/m2 Daunorubicine IV infusion and vincristine 1.5 mg/m2 must be given first day of every week combining prednisone 40mg/me PO. An entire remission of cancer may be observed after four courses of treatment. However, if remission remains partial, an additional 2 courses of treatment is required for complete remission. For children newer 2 years of age and affected roles whose body surface area is below 0.5 m2, dosages of Daunorubicine ought to be measured with respect to weight instead of body surface area.
DAUNORUBICINE SIDE EFFECTS
Daunorubicin may cause a severe reduction in the total number of blood components in the bone marrow. This might lead to certain symptoms and may amplify the risk that you will develop a serious infection or bleeding. Some of the side effects like hair loss, red urine, stomach pain, sores in the mouth and throat, nausea, burning at the site where the injection was given etc. are reported during the treatment. If you experience any of these symptoms or fever higher than 38oC, consult your physician immediately.
Daunorubicine should be used under the guidance of a physician with acute leukaemia and cytotoxic chemotherapy. The treating doctor should weigh the pros and cons of each individual case , on the treatment. Special caution should be taken in patients. The medication should be injected through the vein with other IV fluids. It is not advised to inject the medication into the spinal cavity, that may lead to severe nerve damage. Uncontrolled infections can develop into life-threatening exacerbations after administration of this drug, as daunorubicine’s immunosuppressive effect.
User Reviews for Daunorubicine
Share your experience with other customers.Review This Drug